摘要
对我院2003年～2006年门诊及住院的慢性乙型肝炎患者随机分为对照组（45例）、核苷组（65例）、联合组（复方鳖甲软肝片联合阿得福韦酯）（76例），检测各组HBV—DNA阴转率及肝纤维化指标的变化。结果表明，联合组治疗后HBV-DNA阴转率及肝纤维化指标明显优于核苷组和对照组（P〈0．01）。复方鳖甲软肝片联合阿得福韦酯治疗慢性乙型肝炎能显著提高抗肝纤维化的治疗效果，值得临床推广使用。
The patients with chronic hepatitis B in our hospital from 2003 to 2006 were randomly divided into control group （45 cases） , nucleoside group （65 cases） , comhination treatment group （Fufangbiejiaruanganpian united Adefovir Dipivoxil） （76 eases）. The negative conversion rate of HBV-DNA and changes of HA, LN, PCⅢ and CⅣ in three groups were detected. Compared with control group and nueleoside group, there were significant differences in the negative conversion rate of HBV-DNA and changes of HA, LN, PC Ⅲ and CⅣ in combination treatment group after treatment （ P 〈 0. 01 ）. Fufangbiejiaruanganpian united Adefovir Dipivoxil treatment of chronic hepatitis B could significantly improve the effect of anti-fibrosis.
出处
《胃肠病学和肝病学杂志》
CAS
2009年第2期165-166,共2页
Chinese Journal of Gastroenterology and Hepatology
关键词
复方鳖甲软肝片
阿得福韦酯
慢性乙肝
纤维化
Fufangbiejiaruanganpian
Adefovir Dipivoxil
Chronic hepatitis B
Fibrosis
